Palatin Technologies has turned a once-commercial melanocortin franchise into a partner-funded, still-preclinical rare-obesity story. After selling Vyleesi, assigning retinal patents to Boehringer Ingelheim, and sublicensing the dry-eye candidate, the company now lives or dies on whether a once-weekly peptide and a next-generation oral MC4R agonist reach the clinic before cash and listing patience run out. Cash at March quarter-end was $10 million. Management states that cash plus near-term receivables cover operations through the middle of the following year. That runway is a bridge to an investigational filing, not to a marketed product.
Nine-month collaboration revenue reached $13 million after a year with none. The third-quarter slice was mostly non-cash debt cancellation on the Altanispac sublicense rather than a cash milestone. Operating cash used across the nine months still ran about $11 million, which means last November's underwritten sale, not license quality, rebuilt the pile. The market is paying only a modest premium to cash for a selectivity claim against Rhythm's already-approved MC4R franchise.
The November offering brought about $18 million of gross proceeds and a stack of milestone warrants that can double that haul if exercised. Common shares outstanding nearly doubled from fiscal year-end. Whether the peptide filing lands on the late-calendar timetable, and whether partners send more cash before another equity sale, decides if this recapitalization was a reset or just another bridge.